{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
megestrol acetate
to a specific field?
Status:
US Previously Marketed
Source:
Oil of Lavender U.S.P.
(1921)
Source URL:
First marketed in 1921
Source:
Oil of Lavender U.S.P.
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
US Previously Marketed
First marketed in 1921
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(2017)
Source URL:
First approved in 2017
Source:
21 CFR 348
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 347
(2016)
Source URL:
First approved in 2016
Source:
21 CFR 347
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(2010)
Source URL:
First approved in 2010
Source:
21 CFR 348
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
SG Plus Repellent Aroma Mist by HANKOOK SAMGONG CO.,LTD
(2017)
Source URL:
First approved in 2010
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT03694405: Phase 4 Interventional Completed Meningococcal Disease, Invasive
(2018)
Source URL:
First approved in 2010
Source:
BLA125300
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2010)
Source URL:
First approved in 2010
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT03694405: Phase 4 Interventional Completed Meningococcal Disease, Invasive
(2018)
Source URL:
First approved in 2010
Source:
BLA125300
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT03694405: Phase 4 Interventional Completed Meningococcal Disease, Invasive
(2018)
Source URL:
First approved in 2010
Source:
BLA125300
Source URL:
Class:
STRUCTURALLY DIVERSE